Compare Adaptive Biotechnologies Corp (ADPT) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Workiva Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Workiva Inc trades at $52.51 (market cap $2.97B). The key difference: Adaptive Biotechnologies Corp and Workiva Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | WK | |
|---|---|---|
Market Cap | $3.33B | $2.97B |
Sector | Health | Technology |
52-Week High | $22.37 | $93.31 |
52-Week Low | $10.24 | $44.31 |
Enterprise Value | $3.19B | $2.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Workiva (WK) trades at $51.54, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $0.77, beating estimates, and shows improving revenue trends. Cash flow from operations grew to $140.07M in 2025, with net income turning positive in 2026 projections. Recent news highlights AI adoption in finance and upcoming Q2 2026 earnings.
Outlook remains positive with a consensus price target of $71.00, implying 38% upside, supported by 16 buy ratings. Risks include high valuation multiples (P/E 214.75) and reliance on sustained earnings growth. The stock presents a growth opportunity if execution continues, but volatility near resistance at $52 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
